11 results on '"Bonnici, Jeffrey"'
Search Results
2. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
- Author
-
Waters, Mitchell L., Dargan, Paul I., Yates, Christopher, Dines, Alison M., Eyer, Florian, Giraudon, Isabelle, Heyerdahl, Fridtjof, Hovda, Knut Erik, Liechti, Matthias E., Miró, Òscar, Vallersnes, Odd Martin, Anseeuw, Kurt, Badaras, Robertas, Bitel, Marcin, Bonnici, Jeffrey, Brvar, Miran, Caganova, Blazena, Calýskan, Feriyde, Ceschi, Alessandro, and Chamoun, Karam
- Subjects
CANNABINOID receptors ,SYNTHETIC receptors ,ACUTE toxicity testing ,EMERGENCY room visits ,SYNTHETIC marijuana ,WEEDS - Abstract
Cannabis is the most common recreational drug worldwide and synthetic cannabinoid receptor agonists are currently the largest group of new psychoactive substances. The aim of this study was to compare the clinical features and outcomes of lone acute cannabis toxicity with lone acute synthetic cannabinoid receptor agonist toxicity in a large series of presentations to European emergency departments between 2013-2020. Self-reported drug exposure, clinical, and outcome data were extracted from the European Drug Emergencies Network Plus which is a surveillance network that records data on drug-related emergency department presentations to 36 centres in 24 European countries. Cannabis exposure was considered the control in all analyses. To compare the lone cannabis and lone synthetic cannabinoid receptor agonist groups, univariate analysis using chi squared testing was used for categorical variables and non-parametric Mann-Whitney U- testing for continuous variables. Statistical significance was defined as a P value of <0.05. Between 2013-2020 there were 54,314 drug related presentations of which 2,657 were lone cannabis exposures and 503 lone synthetic cannabinoid receptor agonist exposures. Synthetic cannabinoid receptor agonist presentations had statistically significantly higher rates of drowsiness, coma, agitation, seizures and bradycardia at the time of presentation. Cannabis presentations were significantly more likely to have palpitations, chest pain, hypertension, tachycardia, anxiety, vomiting and headache. Emergency department presentations involving lone synthetic cannabinoid receptor agonist exposures were more likely to have neuropsychiatric features and be admitted to a psychiatric ward, and lone cannabis exposures were more likely to have cardiovascular features. Previous studies have shown variability in the acute toxicity of synthetic cannabinoid receptor agonists compared with cannabis but there is little comparative data available on lone exposures. There is limited direct comparison in the current literature between lone synthetic cannabinoid receptor agonist and lone cannabis exposure, with only two previous poison centre series and two clinical series. Whilst this study is limited by self-report being used to identify the drug(s) involved in the presentations, previous studies have demonstrated that self-report is reliable in emergency department presentations with acute drug toxicity. This study directly compares presentations with acute drug toxicity related to the lone use of cannabis or synthetic cannabinoid receptor agonists. It supports previous findings of increased neuropsychiatric toxicity from synthetic cannabinoid receptor agonists compared to cannabis and provides further data on cardiovascular toxicity in lone cannabis use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014–2019.
- Author
-
Crulli, Benjamin, Dines, Alison M., Blanco, Georgina, Giraudon, Isabelle, Eyer, Florian, Liechti, Matthias E., Miró, Òscar, Hovda, Knut E., Heyerdahl, Fridtjof, Yates, Christopher, Vallersnes, Odd Martin, Wood, David M., Dargan, Paul I., Anand, Lukasz, Anseeuw, Kurt, Badaras, Robertas, Bonnici, Jeffrey, Brvar, Miran, Caganova, Blazena, and Calýskan, Feriyde
- Subjects
HOSPITAL emergency services ,DRUGS of abuse ,LENGTH of stay in hospitals ,DRUG toxicity ,CRITICAL care medicine - Abstract
Novel psychoactive substances (NPS) have been increasingly reported in the last 15–20 years. We aimed to describe presentations to the emergency department (ED) with acute recreational drug toxicity involving NPS. Data were extracted from the European Drug Emergencies Network (Euro-DEN) Plus database for all presentations to ED (36 EDs in 24 European countries) with acute toxicity between January 2014 and December 2019. Patient demographics, agents involved, and clinical outcomes were described and the subgroup of presentations involving NPS was compared with the rest of the cohort. Out of 43,633 Euro-DEN Plus presentations, 3304 (7.6%) involved at least one NPS. Agents were identified mainly based on self-report or clinical presentation, with analytical confirmation being performed only in 17.9% of NPS presentations. The proportion of NPS presentations varied by centre (0–48.8%). For centres where data were available for all 6 years, NPS-related presentations peaked in 2015 (11.9%). In 2014, 78.4% of NPS agents reported were cathinones, while only 3.4% were synthetic cannabinoids (SCs); conversely, in 2019 only 11.6% of NPS agents reported were cathinones, while 72.2% were SCs. NPS-related presentations involved younger patients (median 30 (23–37) vs. 32 (25–40) years, p < 0.001) and more males (84.8 vs. 75.8%, p < 0.001) compared with the rest of the cohort. Patients presenting to ED after using NPS were more likely to self-discharge (22.8 vs. 15.1%), less likely to be admitted to critical care (3.6 vs. 6.1%) but had a longer length of stay in hospital (median 5.1 (2.7–18.7) vs. 4.7 (2.5–9.2) h, p < 0.001). Death occurred in 0.5% of all presentations involving NPS and in 0.4% of non-NPS presentations. This large multicentre series of NPS presentations to European EDs showed marked geographical variation and changes over time in the proportion of presentations to ED involving NPS, as well as the proportion of NPS subgroups. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014–2017
- Author
-
Noseda, Roberta, Schmid, Yasmin, Scholz, Irene, Liakoni, Evangelia, Liechti, Matthias E., Dargan, Paul I., Wood, David M., Dines, Alison M., Yates, Christopher, Heyerdahl, Fridtjof, Hovda, Knut E., Giraudon, Isabelle, Ceschi, Alessandro, Lukasz Anand, Anseeuw, Kurt, Badaras, Robertas, Bonnici, Jeffrey, Brvar, Miran, Burke, Rachel, Blazena Caganova, Eyer, Florian, Galicia, Miguel, Geith, Stefanie, Gillebeert, Johan, Grenc, Damjan, Gorozia, Ketevan, Jaffal, Karim, Jürgens, Gesche, Konstari, Jutta, Kutubidze, Soso, Gabija Laubner, Liguts, Viesturs, Lyphout, Cathelijne, Mégarbane, Bruno, Òscar Miró, Moughty, Adrian, O'Connor, Niall, Paasma, Raido, Perez, Juan Ortega, Perminas, Marius, Persett, Per Sverre, Põld, Kristiina, Puiguriguer, Jordi, Radenkova-Saeva, Julia, Rulisek, Jan, Sopirala, Radhika, Stašinskis, Roberts, Surkus, Jonas, Toth, Ibolya, Vallersnes, Odd Martin, Vigorita, Federico, Waldman, Wojciech, W. Stephen Waring, and Zacharov, Sergej
- Abstract
3,4-Methylenedioxymethamphetamine (MDMA) remains one of the most commonly used recreational drugs in Europe. Monitoring of Emergency Department (ED) presentations with acute toxicity associated with MDMA is important to determine trends in MDMA use and harms. Data were extracted from the European Drug Emergencies Network (Euro-DEN) Plus database for all ED presentations with acute toxicity involving MDMA use, alone or in combination with other substances, between 1 January 2014 and 31 December 2017. Geographical distribution, time trends, patient demographics, clinical features, management and outcome were analysed. Out of 23,947 presentations, 2013 (8.4%) involved MDMA, used alone (88, 4.4%) or with other substances (1925, 95.6%). The proportion of MDMA presentations varied by country, from over 15% in France to less than 5% in Norway. For the 15 sentinel centres where data were available for all four years, MDMA-related presentations peaked in 2016 (10.4% versus 8.1% in 2015, p p = 0.0002). 1436 (71.3%) presentations involved males. Females were significantly younger than males (median 23 years, interquartile range, IQR, 20–27 years, versus median 25 years, IQR 21–30 years, p versus 43.9%, p = 0.02), were more frequently medically discharged directly from the ED (74.7% versus 62.4%, p = 0.03), and less frequently received sedation (43.5% versus 66.5%, p = 0.003). This large multicentre series of MDMA presentations to EDs showed geographical variation and changes in time trends and in patient demographics. Triangulation with data from complementary sources including seizures, prevalence of use and wastewater analysis, will enable a greater understanding of the public health implications of MDMA use in Europe.
- Published
- 2021
- Full Text
- View/download PDF
5. Variation of drugs involved in acute drug toxicity presentations based on age and sex:an epidemiological approach based on European emergency departments
- Author
-
Miró, Òscar, Waring, William S., Dargan, Paul I., Wood, David M., Dines, Alison M., Yates, Christopher, Giraudon, Isabelle, Moughty, Adrian, O'Connor, Niall, Heyerdahl, Fridtjof, Hovda, Knut E., Vallersnes, Odd M., Paasma, Raido, Pold, Kristiina, Jürgens, Gesche, Megarbane, Bruno, Anand, Jacek S., Liakoni, Evangelia, Liechti, Matthias, Eyer, Florian, Zacharov, Sergej, Caganova, Blazena, Bonnici, Jeffrey, Radenkova-Saeva, Julia, Galicia, Miguel, Miró, Òscar, Waring, William S., Dargan, Paul I., Wood, David M., Dines, Alison M., Yates, Christopher, Giraudon, Isabelle, Moughty, Adrian, O'Connor, Niall, Heyerdahl, Fridtjof, Hovda, Knut E., Vallersnes, Odd M., Paasma, Raido, Pold, Kristiina, Jürgens, Gesche, Megarbane, Bruno, Anand, Jacek S., Liakoni, Evangelia, Liechti, Matthias, Eyer, Florian, Zacharov, Sergej, Caganova, Blazena, Bonnici, Jeffrey, Radenkova-Saeva, Julia, and Galicia, Miguel
- Abstract
Objective: To analyse the relative percentage of acute recreational drug toxicity emergency department (ED) presentations involving the main drug groups according to age and sex and investigate different patterns based on sex and age strata. Methods: We analysed all patients with acute recreational drug toxicity included by the Euro-DEN Plus dataset (22 EDs in 14 European countries) between October 2013 and December 2016 (39 months). Drugs were grouped as: opioids, cocaine, cannabis, amphetamines, gamma-hydroxybutyrate (GHB), hallucinogens, new psychoactive substances (NPS), benzodiazepines and ketamine. Descriptive data by age and sex are presented and compared among age/sex categories and among drug families. Results: Of 17,371 patients were included during the 39-month period, 17,198 (99.0%) had taken at least one of the investigated drugs (median age: 31 years; 23.9% female; ethanol co-ingestion recorded in 41.5%, unknown in 31.2%; multiple drug use in 37.9%). Opioids (in 31.4% of patients) and amphetamines (23.3%) were the most frequently involved and hallucinogens (1.9%) and ketamine (1.7%) the least. Overall, female patients were younger than males, both in the whole cohort (median age 29 vs. 32 years; p < 0.001) and in all drug groups except benzodiazepines (median age 36 vs. 36 years; p = 0.83). The relative proportion of each drug group was different at every age strata and some patterns could be clearly described: cannabis, NPS and hallucinogens were the most common in patients <20 years; amphetamines, ketamine and cocaine in the 20- to 39-year group; GHB/GBL in the 30- to 39-year group; and opioids and benzodiazepines in patients ≥40 years. Ethanol and other drug co-ingestion was more frequent at middle-ages, and multidrug co-ingestion was more common in females than males. Conclusion: Differences in the drugs involved in acute drug toxicity presentations according to age and sex may be relevant for developing drug-prevention and education progr
- Published
- 2021
6. Acute toxicity related to misuse (nonmedical use) of tramadol: Experience of the European Drug Emergencies Network Plus
- Author
-
Layne, Kerry, Dargan, Paul, Dines, Alison, Leaper, Craig, Yates, Christopher, Hovda, Knut Erik, Heyerdahl, Fridtjof, Archer, John R.H., Giraudon, Isabelle, Wood, David, Anand, Lukasz, Anseeuw, Kurt, Badaras, Robertas, Bonnici, Jeffrey, Brvar, Miran, Burke, Rachel, Caganova, Blazena, Ceschi, Alessandro, Eyer, Florian, Galicia, Miguel, Geith, Stefanie, Gillebeert, Johan, Grenc, Damjan, Gorozia, Ketevan, Jaffal, Karim, Jürgens, Gesche, Konstari, Jutta, Kutubidze, Soso, Laubner, Gabija, Liakoni, Evangelia, Liechti, Matthias, Liguts, Viesturs, Lyphout, Cathelijne, Mégarbane, Bruno, Miró, Òscar, Moughty, Adrian, Noseda, Roberta, O'Connor, Niall, Paasma, Raido, Perez, Juan Ortega, Perminas, Marius, Persett, Per Sverre, Põld, Kristiina, Puiguriguer, Jordi, Radenkova-Saeva, Julia, Rulisek, Jan, Schmid, Yasmin, Scholz, Irene, Sopirala, Radhika, Stašinskis, Roberts, Surkus, Jonas, Toth, Ibolya, Vallersnes, Odd Martin, Vigorita, Federico, Waldman, Wojciech, Waring, W. Stephen, Zacharov, Sergej, Guy's and St Thomas' Hospital [London], King‘s College London, Hospital Universitari Son Espases, Oslo University Hospital [Oslo], European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Observatoire Européen des Drogues et des Toxicomanies, Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Euro-DEN Plus Research Group, and Mégarbane, Bruno
- Subjects
medicine.medical_specialty ,030226 pharmacology & pharmacy ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Germany ,Medicine ,Humans ,Pharmacology (medical) ,In patient ,030212 general & internal medicine ,Tramadol ,Pharmacology ,Coma ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,business.industry ,Glasgow Coma Scale ,Emergency department ,humanities ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.TOX] Life Sciences [q-bio]/Toxicology ,Analgesics, Opioid ,Europe ,Pharmaceutical Preparations ,[SDV.TOX]Life Sciences [q-bio]/Toxicology ,Emergency medicine ,Africa ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,medicine.symptom ,Emergencies ,business ,Emergency Service, Hospital ,medicine.drug - Abstract
International audience; Following the development of the tramadol crisis currently affecting countries in the Middle East, and Africa, there has been increasing international interest in the regulation of tramadol. This study investigates the misuse of tramadol in patients presenting to emergency departments across Europe. Data from 32 emergency departments in 21 countries were extracted from the Euro-DEN Plus database for the 4-year period from 1 January 2014 to 31 December 2017. Of the reported 24,957 emergency department presentations, tramadol misuse was reported in 105 (0.4% presentations). Tramadol misuse was most common in Bratislava (Slovakia; n = 11, 7.5% of all presentations to this centre), Riga (Latvia; n = 4, 4.9%) and Munich (Germany; n = 17, 2.9%). On arrival, 14 (13.3%) of presentations were in coma/Glasgow coma score ≤ 8 and 9 of these had a respiratory rate
- Published
- 2020
7. Toxic Tea - Case Report.
- Author
-
Bonnici Farrugia, Russell, Agius, Pierre, Bonnici, Jeffrey, and Zammit, Luke
- Subjects
OLEANDER ,TEA extracts ,ABDOMINAL pain ,TEA ,RITES & ceremonies - Abstract
A young gentleman presents with deliberate unidentified plant ingestion, complaining of abdominal pain and vomiting. He is found to have junctional rhythm at 37 beats per minute. On further questioning, he is noted to have ingested Nerium oleander leaf tea extract as part of a ritual. The mechanism of action, diagnosis and management of oleander poisoning is discussed in this case report. Awareness to the common oleander plant and its toxicity in the Maltese islands and around the Mediterranean is emphasized. [ABSTRACT FROM AUTHOR]
- Published
- 2023
8. Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication
- Author
-
Galicia, Miguel, primary, Dargan, Paul I., additional, Dines, Alison M., additional, Yates, Christopher, additional, Heyerdahl, Fridtjof, additional, Hovda, Knut Erik, additional, Giraudon, Isabella, additional, Wood, David M., additional, Miró, Òscar, additional, Anand, Jacek Sein, additional, Bonnici, Jeffrey, additional, Caganova, Blazena, additional, Eyer, Florian, additional, Jürgens, Gesche, additional, Kabata, Piotr Maciej, additional, Liakoni, Evangelia, additional, Liechti, Matthias E, additional, Mégarbane, Bruno, additional, Moughty, Adrian, additional, O'Connor, Niall, additional, Paasma, Raido, additional, Persett, Per Sverre, additional, Põld, Kristiina, additional, Radenkova–Saeva, Julia, additional, Scholz, Irene, additional, Vallersnes, Odd Martin, additional, Waring, W Stephen, additional, and Zacharov, Sergej, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set
- Author
-
Wolfe, Caitlin E., primary, Wood, David M., additional, Dines, Alison, additional, Whatley, Benjamin P., additional, Yates, Christopher, additional, Heyerdahl, Fridtjof, additional, Hovda, Knut Erik, additional, Giraudon, Isabelle, additional, Dargan, Paul I., additional, Anseeuw, Kurt, additional, Badaras, Robertas, additional, Bonnici, Jeffrey, additional, Brvar, Miran, additional, Caganova, Blazena, additional, Ceschi, Alessandro, additional, Eyer, Florian, additional, Galicia, Miguel, additional, Geith, Stefanie, additional, Gillebeert, Johan, additional, Grenc, Damjan, additional, Gorozia, Ketevan, additional, Jaffal, Karim, additional, Jürgens, Gesche, additional, Kabata, Piotr Maciej, additional, Kennedy, Iarlaith, additional, Konstari, Jutta, additional, Kutubidze, Soso, additional, Laubner, Gabija, additional, Liakoni, Evangelia, additional, Liechti, Matthias E., additional, Lyphout, Cathelijne, additional, Mégarbane, Bruno, additional, Miró, Òscar, additional, Moughty, Adrian, additional, Müller, Laura, additional, O'Connor, Niall, additional, Paasma, Raido, additional, Perez, Juan Ortega, additional, Perminas, Marius, additional, Persett, Per Sverre, additional, Põld, Kristiina, additional, Puiguriguer, Jordi, additional, Radenkova-Saeva, Julia, additional, Rulisek, Jan, additional, Schmid, Yasmin, additional, Scholz, Irene, additional, Sopirala, Radhika, additional, Surkus, Jonas, additional, Toth, Ibolya, additional, Vallersnes, Odd Martin, additional, Vigorita, Federico, additional, Waldman, Wojciech, additional, Waring, W. Stephen, additional, and Zacharov, Sergej, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Recreational drug use and the emerging challenges of psychoactive substances in Malta : a case series
- Author
-
Bonnici, Jeffrey, Coulson, James, and Gauci, Dorothy
- Subjects
Psychotropic drugs -- Malta ,Synthetic drugs ,Synthetic marijuana ,Drug abuse -- Malta ,Cannabinoids - Abstract
Introduction: Recreational drug-related hospital admissions, excluding alcohol, appeared to be relatively constant in Mater Dei Hospital (MDH), Malta’s sole public, acute general hospital. While ‘classical’ recreational drugs such as cocaine, heroin and Methylenedioxymethamphetamine (MDMA) were always seen as the main culprits, intoxications secondary to novel psychoactive substances (NPS) have recently emerged in MDH. The aim of this study was to determine the challenges of recreational drug intoxication, including NPS, in MDH. Methods: All the MDH admissions secondary to recreational drug intoxication between 2010 and 2015 were investigated. MDH clinical performance unit (CPU), hospital data files, hospital discharge letters and the hospital database software system were utilised for data collection. Intoxications associated with self-harm, trauma and lone alcohol ingestions were excluded. Results: 286 patients were admitted to MDH with recreational drug intoxication between 2010-2015, with a peak of 71 patients in 2015. 78.3% were males and the median age was 26 years. While 79% of the admissions were Maltese nationals, there was a surge in foreigner admissions, from 11.8% between 2010-2012 to 28.3% between 2013-2015 (p, peer-reviewed
- Published
- 2017
11. Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments.
- Author
-
Miró Ò, Waring WS, Dargan PI, Wood DM, Dines AM, Yates C, Giraudon I, Moughty A, O'Connor N, Heyerdahl F, Hovda KE, Vallersnes OM, Paasma R, Pold K, Jürgens G, Megarbane B, Anand JS, Liakoni E, Liechti M, Eyer F, Zacharov S, Caganova B, Bonnici J, Radenkova-Saeva J, and Galicia M
- Subjects
- Acute Disease, Adolescent, Adult, Age Factors, Aged, Databases, Factual, Europe epidemiology, Female, Humans, Illicit Drugs classification, Male, Middle Aged, Poisoning diagnosis, Registries, Risk Assessment, Risk Factors, Sex Factors, Substance-Related Disorders diagnosis, Time Factors, Young Adult, Emergency Service, Hospital trends, Illicit Drugs poisoning, Poisoning epidemiology, Recreational Drug Use trends, Substance-Related Disorders epidemiology
- Abstract
Objective: To analyse the relative percentage of acute recreational drug toxicity emergency department (ED) presentations involving the main drug groups according to age and sex and investigate different patterns based on sex and age strata., Methods: We analysed all patients with acute recreational drug toxicity included by the Euro-DEN Plus dataset (22 EDs in 14 European countries) between October 2013 and December 2016 (39 months). Drugs were grouped as: opioids, cocaine, cannabis, amphetamines, gamma-hydroxybutyrate (GHB), hallucinogens, new psychoactive substances (NPS), benzodiazepines and ketamine. Descriptive data by age and sex are presented and compared among age/sex categories and among drug families., Results: Of 17,371 patients were included during the 39-month period, 17,198 (99.0%) had taken at least one of the investigated drugs (median age: 31 years; 23.9% female; ethanol co-ingestion recorded in 41.5%, unknown in 31.2%; multiple drug use in 37.9%). Opioids (in 31.4% of patients) and amphetamines (23.3%) were the most frequently involved and hallucinogens (1.9%) and ketamine (1.7%) the least. Overall, female patients were younger than males, both in the whole cohort (median age 29 vs. 32 years; p < 0.001) and in all drug groups except benzodiazepines (median age 36 vs. 36 years; p = 0.83). The relative proportion of each drug group was different at every age strata and some patterns could be clearly described: cannabis, NPS and hallucinogens were the most common in patients <20 years; amphetamines, ketamine and cocaine in the 20- to 39-year group; GHB/GBL in the 30- to 39-year group; and opioids and benzodiazepines in patients ≥40 years. Ethanol and other drug co-ingestion was more frequent at middle-ages, and multidrug co-ingestion was more common in females than males., Conclusion: Differences in the drugs involved in acute drug toxicity presentations according to age and sex may be relevant for developing drug-prevention and education programs for some particular subgroups of the population based on the increased risk of adverse events in specific sex and/or age strata.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.